Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study
用户EO9nReo4Hj6s
2个月前
103
10
已完结
1. 系统已在2026-08-28 00:12:52对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.annonc.2026.05.692
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0923753426008768
其他信息:
出版社: Elsevier BV
作者: A.T. Shaw; B.J. Solomon; E. Felip; T.M. Bauer; G. Liu; Y. Goto; Y.-L. Wu; R.A. Soo; J. Mazieres; D.-W. Kim; I.-M. Wang; J. Paolini; A. Polli; N. Rifi; F. Toffalorio; T.S.K. Mok
